McDonnell Boehnen Hulbert & Berghoff LLP is proud to be an official sponsor of the 2016 BIO IP & Diagnostics Symposium set for September 29, 2016 in Alexandria, VA. MBHB partners Dr. Kevin Noonan and Dr. Donald Zuhn, Jr. are set to participate as featured presenters for Session 3 of the event.
Session 3 (11:00 a.m. – 12:15 p.m.): How Diagnostics can be Developed in a Post-Mayo World
Sponsored by: McDonnell Boehnen Hulbert & Berghoff LLP
The patenting landscape surrounding diagnostic methods has been thrown into disarray by several U.S. Supreme Court decisions over the past five years. One of the predicted consequences of the current patent situation is that it is inimical to investment, because the uncertainty caused by the Supreme Court makes it much more likely that the patents providing exclusivity on a diagnostic method claim can be invalidated by an infringer. Indeed, that is exactly what happened to Sequenom on its prenatal diagnostics blood test, and the Court refused to reconsider its precedent even in the face of evidence the infringer intentionally used the law to be able to take advantage of the investment Sequenom had made in developing the technology. This panel will discuss the present and potentially long-term effects of this situation on the development of diagnostic methods in the U.S.
Featured Presenters:
About the BIO IP & Diagnostics Symposium
The Symposium program will review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. Sessions will review IP issues for both diagnostics generally and companion diagnostics. Programming will also explore new collaborations and regulatory developments. BIO aims to use this event to inform industry and government alike on how to move the science forward in the current climate.
Who Should Attend?
This event is primarily geared towards patent practitioners in the life sciences, both in-house and in private practice. In-house regulatory affairs staff, licensing professionals, business development executives and regulatory agency staff seeking to understand the special premarketing and intellectual property challenges in this area would likewise benefit.
View registration details here